American Society of Clinical Oncology (ASCO)

This post hoc tolerability analysis of duvelisib found that dose interruptions or reductions did not adversely affect response to treatment for most patients. Read More ›

Long-term follow-up of patients receiving ibrutinib showed sustained efficacy, low rates of discontinuation, and acceptable tolerability with no new safety signals over time. This analysis provides additional evidence supporting ibrutinib as standard of care in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Read More ›

In a phase 2 study, the next-generation PI3Kδ inhibitor umbralisib demonstrated efficacy and safety when given as monotherapy in patients with relapsed or refractory marginal zone lymphoma (MZL). Read More ›

In prior research, chimeric antigen receptor (CAR) T-cell therapy has shown encouraging clinical activity in hematologic malignancies. The study design for the ZUMA-8 phase 1/2 trial evaluating the investigational CAR T-cell therapy KTE-X19 was presented at the ASCO 2019 Annual Meeting. Read More ›

The phase 1 portion of a clinical trial combining the novel monoclonal antibody cirmtuzumab with ibrutinib yielded promising results, and investigators will move forward with the phase 2 portion of the trial. Read More ›

At 19 months of follow-up, ibrutinib maintenance in mantle-cell lymphoma (MCL) shows promising efficacy with acceptable tolerability. Future reports are expected to provide additional insight into this potential new option for MCL maintenance therapy after induction. Read More ›

Preclinical studies show that the spleen tyrosine kinase (SYK) inhibitor R406 exhibits a mechanism of action that makes it a logical target for clinical exploration in Waldenström’s macroglobulinemia. Read More ›

A systematic review of 11 studies found that ibrutinib is effective and well-tolerated when administered in combination with a range of other therapeutic agents for the treatment of patients with mantle-cell lymphoma. Read More ›

Recent data from the phase 3 CLL14 trial indicate that a combination of venetoclax plus obinutuzumab, given as fixed-duration therapy, showed impressive and sustained MRD-negative rates, translating into improved progression-free survival. Read More ›

Phase 2 data show that continuation of Bruton’s tyrosine kinase treatment with acalabrutinib may represent a viable treatment strategy in patients with CLL who have become intolerant to ibrutinib and whose disease has progressed. Read More ›